HCAT

Health Catalyst, Inc. (HCAT) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2024. Health Catalyst, Inc. is a leading provider of data and analytics technology and services to healthcare organizations. The company operates through two segments: Technology (cloud-based data platform and analytics applications) and Professional Services (analytics, implementation, and managed services). The company is currently migrating clients to its next-generation platform, "Health Catalyst Ignite," and transitioning hosting to Microsoft Azure.

Key Financial Metrics

Note: Convertible Senior Notes due 2025 were reclassified as current liabilities in Q2 2024 as the maturity date (April 2025) is within 12 months.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 4% year-over-year (Q2) and 2% year-over-year (YTD). Growth was driven by new clients and expansion in Tech-enabled Managed Services (TEMS), partially offset by elevated churn in certain clinical offerings.
• Profitability Improvement: Net loss narrowed significantly, decreasing 59% in Q2 and 48% YTD compared to 2023. This improvement is attributed to cost reduction initiatives, including the 2023 Restructuring Plan, and the absence of the $21.3 million litigation settlement charge recorded in the prior year.
• Operating Expenses: General and Administrative (G&A) expenses decreased 39% in Q2 and 39% YTD, primarily due to the absence of prior-year litigation costs and lease impairment charges. Sales and Marketing and R&D expenses also declined due to reduced headcount and lower stock-based compensation.
• Acquisitions: The company acquired Carevive Systems, Inc. in May 2024 for approximately $22.1 million. Subsequent to the period end, the company acquired Lumeon Ltd. in August 2024.

Guidance, Outlook, and Risks

• Outlook: Management anticipates higher bookings in the second half of 2024. They expect average subscription revenue for new clients in 2024 to range between $400,000 and $1,000,000, driven by modular additions to the Health Catalyst Ignite platform. While near-term gross margins may face headwinds due to platform migrations and Azure hosting costs, long-term Adjusted EBITDA is expected to improve.
• Debt & Liquidity: On July 16, 2024 (subsequent to period end), the company entered a $225 million credit agreement ($125 million initial term loan funded) to repay the Convertible Notes and fund acquisitions. The company holds approximately $308 million in cash and short-term investments.
• Risks:
  • Client Financial Health: One major client, Steward Health Care, filed for Chapter 11 bankruptcy in May 2024. As of June 30, this client represented approximately 15% of outstanding accounts receivable.
  • Macroeconomic Environment: High inflation and interest rates continue to strain healthcare systems, potentially leading to reduced spending or contract renegotiations.
  • Migration Costs: Transitioning clients to Azure and the new Ignite platform is expected to increase costs of revenue in the near term.

Key Facts for Investor Verification

• Convertible Notes Maturity: Verify the company's plan and ability to repay or refinance the $230 million Convertible Senior Notes maturing in April 2025, noting the recent $125 million term loan secured in July 2024.
• Steward Health Care Exposure: Monitor the resolution of the bankruptcy filing of Steward Health Care, which held ~15% of the company's accounts receivable at quarter-end.
• Gross Margin Trends: Track the impact of the migration to Microsoft Azure and Health Catalyst Ignite on Technology Gross Margins, which management expects to face near-term pressure.
• Churn Rates: Assess the company's ability to stabilize churn levels, particularly in clinically-focused technology offerings, as noted in the MD&A.
• Acquisition Integration: Evaluate the integration progress and financial impact of the Carevive (May 2024) and Lumeon (August 2024) acquisitions.